ANG Lifesciences India Limited Stock

Equities

ANG6

INE236W01016

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-26 EDT 5-day change 1st Jan Change
57.2 INR -0.33% Intraday chart for ANG Lifesciences India Limited +0.37% -17.59%

Financials

Sales 2022 3.54B 42.49M 58.1M Sales 2023 2.2B 26.37M 36.06M Capitalization 993M 11.91M 16.28M
Net income 2022 403M 4.83M 6.61M Net income 2023 -2M -23.99K -32.8K EV / Sales 2022 0.88 x
Net Debt 2022 703M 8.44M 11.53M Net Debt 2023 666M 7.99M 10.92M EV / Sales 2023 0.75 x
P/E ratio 2022
6.03 x
P/E ratio 2023
-377 x
Employees 545
Yield 2022
0.43%
Yield 2023
-
Free-Float 29.4%
More Fundamentals * Assessed data
Dynamic Chart
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
ANG Lifesciences India CFO Steps Down MT
ANG Lifesciences India Limited Announces Resignation of Neeraj Gupta as Chief Financial Officer CI
ANG Lifesciences India Limited Appoints Rohit Mittal as Additional Director (Non-Executive Non Independent Director) CI
ANG Lifesciences India Limited Informs Mrs. Sudesh Kumari Resigns as Non-Executive Non Independent Director CI
ANG Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
ANG Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
ANG Lifesciences India Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
ANG Lifesciences India Limited Appoints Neeraj Gupta as the CFO CI
ANG Lifesciences India Limited announced that it expects to receive INR 60.5 million in funding from ANG Capital Investments Private Limited CI
ANG Lifesciences India Limited announced that it expects to receive INR 60.5 million in funding from ANG Capital Investments Private Limited CI
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
ANG Lifesciences India CFO Resigns MT
ANG Lifesciences India Limited Announces Resignation of Subodh Sharma as Chief Financial Officer CI
More news
1 day-0.33%
1 week+0.37%
Current month+26.89%
1 month+16.05%
3 months-20.65%
6 months-13.10%
Current year-17.59%
More quotes
1 week
56.02
Extreme 56.02
59.00
1 month
44.49
Extreme 44.49
63.17
Current year
44.49
Extreme 44.49
86.06
1 year
44.49
Extreme 44.49
86.99
3 years
42.44
Extreme 42.44
640.36
5 years
10.62
Extreme 10.62
640.36
10 years
10.62
Extreme 10.62
640.36
More quotes
Managers TitleAgeSince
Founder 52 16-07-13
Compliance Officer 32 21-08-05
Chief Administrative Officer - 13-12-31
Members of the board TitleAgeSince
Founder 52 16-07-13
Director/Board Member 76 11-03-31
Director/Board Member 56 16-05-01
More insiders
Date Price Change Volume
24-04-26 57.2 -0.33% 11,370
24-04-25 57.39 +0.24% 4,076
24-04-24 57.25 +0.86% 14,967
24-04-23 56.76 -0.87% 7,703
24-04-22 57.26 +0.47% 2,788

Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am

More quotes
ANG Lifesciences India Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. It operates in two segments, namely pharmaceuticals and printing and packagings. The Company's products portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. It is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syru ps and Suspension, and Lotions, among others. The Company's subsidiaries include ANG Lifesciences India Limited and Mansa Prints and Publishers Limited.
More about the company